A Phase 3 interventional study of Levetiracetam and Placebo in Epilepsy, sponsored by UCB Pharma. Completed. Open to participants aged 4 Years to 16 Years. Per ClinicalTrials.gov, last updated 2020-07-30.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.
Among the 60 studies testing levetiracetam in Epilepsy, this one is the 16th largest by enrollment, is the only one that started in 1999, is one of 28 in phase 3, and was the 28th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+
Waad Alkathiri · Sites in Saudi Arabia
Ages 18+
Xiangya Hospital of Central South University · Sites in China
Ages 18–80
National Taiwan University Hospital
Ages 20+
By country, each count listing its studies:
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 4 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 28 · Phase 4 13
First in 1998; this study’s year is marked. 1 started in 1999.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 216 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 60 interventional studies. Of the 55 that completed or were terminated, 31 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 42nd largest by enrollment of the 116 interventional ones that give a count, is the only one that started in 1999, is one of 74 in phase 3, and was the 46th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing levetiracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Double-blind, randomized, placebo-controlled, multi-center clinical trial conducted to evaluate levetiracetam as adjunctive therapy in children (4-16 years) with refractory partial onset seizures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
LEV dose was titrated to a level of 60 mg/kg/day. The initial dose level was 20 mg/kg/day for the first two weeks, followed by a dose level of 40 mg/kg/day for two weeks. If lower doses were well tolerated, the LEV dose was increased to a dose level of 60 mg/kg/day for the remaining 10 weeks. The dose level could be reduced to 40 mg/kg/day if the patient did not tolerate LEV at a dose level of 60 mg/kg/day.
Drug: Levetiracetam
Subjects received Placebo matching to LEV treatment.
Drug: Placebo
* high total tablet weight (HTTW) formulation in tablet strengths of 166.5 mg, 250 mg, and 500 mg was used for patients weighing at least 40.1 kg * low total tablet weight (LTTW) formulation in tablet strengths of 166 mg and 250 mg was used for patients weighing 40 kg or less
Placebo tablets for oral administration that were identical in appearance to the respective formulations (LTTW and HTTW) were used as reference therapy
Partial onset seizure frequency (Type I, Type IC included) per week during the Treatment period
Calculated as 7-day partial onset seizure frequency.
Time frame: During the 14-weeks Treatment period (Week 8 to Week 22)
50% responder rate in seizure frequency per week during the Treatment Period
Response rate is defined as percent of patients experiencing at least a 50% reduction from baseline in the seizure frequency per week during the Treatment Period.
Time frame: During the 14-weeks Treatment period (Week 8 to Week 22)
Percent of patients with categorized reduction from baseline in seizure frequency per week during the Treatment Period
Categories as follows: \<-25%, -25% to \<25%, 25% to \<50%, 50% to \<75%, 75% to \<100%, and 100%
Time frame: From Baseline to the 14-weeks Treatment period
Change from baseline in the average duration of seizure free intervals
Intervals are defined as seizure-free if no seizures are reported.
Time frame: From Baseline to the 14-weeks Treatment period
Number of seizure free days during the Treatment Period
A day is regarded as seizure-free if no seizures are reported.
Time frame: During the 14-weeks Treatment period (Week 8 to Week 22)
Absolute change from baseline in partial onset seizure frequency per week during the Treatment Period
Absolute change from baseline in partial onset seizure frequency during the Treatment Period standardized to 1 week period. A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.
Time frame: Baseline, During the 14-weeks Treatment period (Week 8 to Week 22)
Absolute change from baseline in partial onset seizure frequency per week during the Titration Period
Absolute change from baseline in partial onset seizure frequency during the Titration Period standardized to 1 week period. A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.
Time frame: Baseline, During the 6-weeks Titration period (Week 8 to Week 14)
Absolute change from baseline in partial onset seizure frequency per week during the Evaluation Period
Absolute change from baseline in partial onset seizure frequency during the Evaluation Period standardized to 1 week period. A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.
Time frame: Baseline, During the 8-weeks Evaluation period (Week 14 to Week 22)
Percent change from baseline in partial onset seizure frequency per week during the Treatment Period
Percent change from baseline in partial onset seizure frequency during the Treatment Period standardized to 1 week period. A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.
Time frame: Baseline, During the 14-weeks Treatment period (Week 8 to Week 22)
Percent change from baseline in partial onset seizure frequency per week during the Titration Period
Percent change from baseline in partial onset seizure frequency during the Titration Period standardized to 1 week period. A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.
Time frame: Baseline, During the 6-weeks Titration period (Week 8 to Week 14)
Percent change from baseline in partial onset seizure frequency per week during the Evaluation Period
Percent change from baseline in partial onset seizure frequency during the Evaluation Period standardized to 1 week period. A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.
Time frame: Baseline, During the 8-weeks Evaluation period (Week 14 to Week 22)
Cumulative percentage of patients who were seizure-free since the beginning of the Evaluation Period
A subject was regarded as seizure-free if not seizures were reported since the beginning of the Evaluation Period.
Time frame: Beginning of the Evaluation Period (Week 14)
Partial onset seizure frequency per week during the Titration Period
Calculated as 7-day partial onset seizure frequency.
Time frame: During the 6-weeks Titration period (Week 8 to Week 14)
Partial onset seizure frequency per week during the Evaluation Period
Calculated as 7-day partial onset seizure frequency.
Time frame: During the 6-weeks Evaluation period (Week 8 to Week 14)
Total seizure frequency per week (Types I + II + III) during the Treatment Period
Calculated as 7-day partial onset seizure frequency.
Time frame: During the 14-weeks Treatment period (Week 8 to Week 22)
Total seizure frequency per week (Types I + II + III) during the Titration Period
Calculated as 7-day partial onset seizure frequency.
Time frame: During the 6-weeks Titration period (Week 8 to Week 14)
Total seizure frequency per week (Types I + II + III) during the Evaluation Period
Calculated as 7-day partial onset seizure frequency.
Time frame: During the 6-weeks Evaluation period (Week 8 to Week 14)
No study locations are listed for this record.
Ran from Sep 1999 to primary completion in Mar 2003, 42 months.
Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 42 months is below that.
Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam